Literature DB >> 7529672

Up-regulation of E-selectin and intercellular adhesion molecule-1 differs between Crohn's disease and ulcerative colitis.

N Pooley1, L Ghosh, P Sharon.   

Abstract

In present study, we investigated if inflammatory mediators secreted by the inflamed colonic mucosa from patients with Crohn's disease and ulcerative colitis had the ability to up-regulate the expression of two adhesion molecules, E-selectin and intercellular adhesion molecule-1. Organ culture techniques and enzyme-linked immunoassays were used to quantify these up-regulations in human umbilical vein endothelial cells. Our results show that, in Crohn's disease patients, the expression of E-selectin was up-regulated 5.5-fold over control values and intercellular adhesion molecule-1 expression was increased 2.4-fold. In ulcerative colitis patients, E-selectin expression was up-regulated twofold over controls with only a 1.5-fold increase in intercellular adhesion molecule-1 expression. Histologically, there was no difference in the degree of inflammation between the two disease groups. Sulfasalazine, in a dose-dependent manner, inhibited E-selectin expression up to 58% and intercellular adhesion molecule-1 up to 62% when stimulated by lipopolysaccharide. The up-regulation of E-selectin and intercellular adhesion molecule-1 may play an important role in mediating the inflammatory process in inflammatory bowel disease. The observed difference between Crohn's disease and ulcerative colitis may reflect differences in inflammatory cell infiltrates or the histopathological differences between the two diseases.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7529672     DOI: 10.1007/bf02063969

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  23 in total

Review 1.  Selectins: interpreters of cell-specific carbohydrate information during inflammation.

Authors:  L A Lasky
Journal:  Science       Date:  1992-11-06       Impact factor: 47.728

2.  The value of rectal biopsy in the diagnosis of ulcerative colitis.

Authors:  S G MATTS
Journal:  Q J Med       Date:  1961-10

3.  Intestinal immune reactivity to interleukin 2 differs among Crohn's disease, ulcerative colitis, and controls.

Authors:  K Kusugami; K R Youngman; G A West; C Fiocchi
Journal:  Gastroenterology       Date:  1989-07       Impact factor: 22.682

4.  Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine.

Authors:  T T MacDonald; P Hutchings; M Y Choy; S Murch; A Cooke
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

5.  Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine.

Authors:  P Sharon; M Ligumsky; D Rachmilewitz; U Zor
Journal:  Gastroenterology       Date:  1978-10       Impact factor: 22.682

6.  Expression of leukocyte adhesion molecules by mucosal mononuclear phagocytes in inflammatory bowel disease.

Authors:  G Malizia; A Calabrese; M Cottone; M Raimondo; L K Trejdosiewicz; C J Smart; L Oliva; L Pagliaro
Journal:  Gastroenterology       Date:  1991-01       Impact factor: 22.682

Review 7.  Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development.

Authors:  M A Peppercorn
Journal:  Ann Intern Med       Date:  1984-09       Impact factor: 25.391

8.  Endotoxemia in human septic shock.

Authors:  R L Danner; R J Elin; J M Hosseini; R A Wesley; J M Reilly; J E Parillo
Journal:  Chest       Date:  1991-01       Impact factor: 9.410

9.  The effect of sulfasalazine on bovine endothelial cell proliferation and cell cycle phase distribution. Comparison with olsalazine, 5-aminosalicylic acid, and sulfapyridine.

Authors:  P Sharon; E A Drab; J S Linder; S W Weidman; S M Sabesin; D B Rubin
Journal:  J Lab Clin Med       Date:  1992-01

Review 10.  A review of assay methods for cyclosporin. Clinical implications.

Authors:  K T Kivistö
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

View more
  14 in total

1.  Poor diagnostic value of colonic CD44v6 expression and serum concentrations of its soluble form in the differentiation of ulcerative colitis from Crohn's disease.

Authors:  W Reinisch; K H Heider; G Oberhuber; C Dejaco; M Müllner; G R Adolf; C Gasché
Journal:  Gut       Date:  1998-09       Impact factor: 23.059

2.  Elevated serum concentrations of soluble selectin and immunoglobulin type adhesion molecules in patients with inflammatory bowel disease.

Authors:  M Göke; J C Hoffmann; J Evers; H Krüger; M P Manns
Journal:  J Gastroenterol       Date:  1997-08       Impact factor: 7.527

Review 3.  Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis.

Authors:  Saskia Thomas; Daniel C Baumgart
Journal:  Inflammopharmacology       Date:  2011-12-20       Impact factor: 4.473

4.  Gene polymorphisms and serological markers of patients with active Crohn's disease in a clinical trial of antisense to ICAM-1.

Authors:  B R Yacyshyn; A Schievella; K L Sewell; J A Tami
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

Review 5.  Genetic update on inflammatory factors in ulcerative colitis: Review of the current literature.

Authors:  Patricia Sarlos; Erzsebet Kovesdi; Lili Magyari; Zsolt Banfai; Andras Szabo; Andras Javorhazy; Bela Melegh
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

6.  Protective effect of comaruman, a pectin of cinquefoil Comarum palustre L., on acetic acid-induced colitis in mice.

Authors:  Sergey V Popov; Raisa G Ovodova; Pavel A Markov; Ida R Nikitina; Yury S Ovodov
Journal:  Dig Dis Sci       Date:  2006-08-22       Impact factor: 3.199

7.  Anti-inflammatory effects of pancreatitis associated protein in inflammatory bowel disease.

Authors:  M Gironella; J L Iovanna; M Sans; F Gil; M Peñalva; D Closa; R Miquel; J M Piqué; J Panés
Journal:  Gut       Date:  2005-05-03       Impact factor: 23.059

8.  Fab'-bearing siRNA TNFα-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis.

Authors:  Hamed Laroui; Emilie Viennois; Bo Xiao; Brandon S B Canup; Duke Geem; Timothy L Denning; Didier Merlin
Journal:  J Control Release       Date:  2014-05-05       Impact factor: 9.776

9.  Expression of ICAM-1 in colon epithelial cells: an ultrastructural study performed on in vivo and in vitro models.

Authors:  Ben Vainer; Susanne Sørensen; Jakob Seidelin; Ole Haagen Nielsen; Thomas Horn
Journal:  Virchows Arch       Date:  2003-10-16       Impact factor: 4.064

10.  Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease.

Authors:  B R Yacyshyn; W Y Chey; J Goff; B Salzberg; R Baerg; A L Buchman; J Tami; R Yu; E Gibiansky; W R Shanahan
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.